As­traZeneca drops or di­vests a slate of drugs in lat­est quar­ter­ly up­date; Pierre Fab­re ex­tends a di­ag­nos­tic col­lab­o­ra­tion with Roche

→ With prof­its in de­cline as gener­ic Crestor com­pe­ti­tion bits in­to its cash flow, As­traZeneca not­ed the end of sev­er­al in-house pro­grams to­day as they cut some ear­ly-stage ef­forts and in­di­cat­ed the di­vesti­ture of oth­ers. Two mid-stage drugs are gone from the pipeline, with the rheuma­toid arthri­tis drug mavril­i­mum­ab now at Kiniksa and inebe­lizum­ab hand­ed off to their spin­out Viela. ME­DI-565, a BiTE part­nered with Am­gen, is out, along with the Sjö­gren’s syn­drome  drug ME­DI4920 (di­vest­ed) and ME­DI7734 as well as the atopic der­mati­tis ther­a­py ME­DI9314.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.